NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $3.66 +0.25 (+7.33%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$3.55 -0.11 (-3.01%) As of 03/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Relay Therapeutics Stock (NASDAQ:RLAY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relay Therapeutics alerts:Sign Up Key Stats Today's Range$3.35▼$3.6650-Day Range$3.19▼$4.9252-Week Range$3.02▼$10.72Volume2.13 million shsAverage Volume2.28 million shsMarket Capitalization$620.45 millionP/E RatioN/ADividend YieldN/APrice Target$19.80Consensus RatingModerate Buy Company OverviewRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Relay Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreRLAY MarketRank™: Relay Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 649th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingRelay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Relay Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.55) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.11% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 2.53%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.11% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 2.53%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.86 News SentimentRelay Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Relay Therapeutics this week, compared to 4 articles on an average week.Search Interest3 people have searched for RLAY on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,491,157.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Stock News HeadlinesRelay Therapeutics’ SWOT analysis: stock poised for growth amid challengesMarch 14 at 6:32 AM | investing.comRelay Therapeutics (NASDAQ:RLAY) Earns Buy Rating from HC WainwrightMarch 10, 2025 | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…March 15, 2025 | Investors Alley (Ad)Analysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $19.80March 5, 2025 | americanbankingnews.comRelay Therapeutics price target lowered to $12 from $21 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 28, 2025 | markets.businessinsider.comRelay Therapeutics reports Q4 EPS (45c), consensus (55c)February 27, 2025 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 27, 2025 | markets.businessinsider.comSee More Headlines RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $4.12 at the beginning of the year. Since then, RLAY shares have decreased by 11.2% and is now trading at $3.66. View the best growth stocks for 2025 here. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) released its earnings results on Wednesday, February, 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Top institutional shareholders of Relay Therapeutics include Vanguard Group Inc. (8.98%), Casdin Capital LLC (5.35%), Tang Capital Management LLC (4.82%) and Norges Bank (3.45%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings2/26/2025Today3/15/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$24.00 Low Stock Price Target$16.00 Potential Upside/Downside+441.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net MarginsN/A Pretax Margin-3,449.57% Return on Equity-45.75% Return on Assets-40.75% Debt Debt-to-Equity RatioN/A Current Ratio18.42 Quick Ratio18.42 Sales & Book Value Annual Sales$10.01 million Price / Sales62.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book0.62Miscellaneous Outstanding Shares169,522,000Free Float160,152,000Market Cap$620.45 million OptionableOptionable Beta1.65 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:RLAY) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.